These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 31536773

  • 1. Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates.
    Santostefano M, Herzyk D, Montgomery D, Wolf J.
    Regul Toxicol Pharmacol; 2019 Nov; 108():104476. PubMed ID: 31536773
    [Abstract] [Full Text] [Related]

  • 2. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
    Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, Bowman EP, Mehta A, Li Q, Zhou Y, Shames R.
    Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tildrakizumab for the treatment of psoriasis.
    Bangert C, Kopp T.
    Immunotherapy; 2018 Sep; 10(13):1105-1122. PubMed ID: 30081696
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis.
    Jauslin P, Kulkarni P, Li H, Vatakuti S, Hussain A, Wenning L, Kerbusch T.
    Clin Pharmacokinet; 2019 Aug; 58(8):1059-1068. PubMed ID: 30915660
    [Abstract] [Full Text] [Related]

  • 10. Tildrakizumab: monoclonal antibody against IL-23p19 for moderate to severe psoriasis.
    Paton DM.
    Drugs Today (Barc); 2018 Jul; 54(7):433-444. PubMed ID: 30090880
    [Abstract] [Full Text] [Related]

  • 11. Tildrakizumab: A Review of Phase II and III Clinical Trials.
    Kolli SS, Gabros SD, Pona A, Cline A, Feldman SR.
    Ann Pharmacother; 2019 Apr; 53(4):413-418. PubMed ID: 30345790
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pre- and postnatal development in the cynomolgus monkey following administration of ABT-874, a human anti-IL-12/23p40 monoclonal antibody.
    Enright BP, Tornesi B, Weinbauer GF, Blaich G.
    Birth Defects Res B Dev Reprod Toxicol; 2012 Dec; 95(6):431-43. PubMed ID: 23212752
    [Abstract] [Full Text] [Related]

  • 16. Tildrakizumab for Moderate-to-Severe Plaque Psoriasis.
    Mui UN, Patel RR, Vangipuram R, Tyring SK.
    Skin Therapy Lett; 2019 Nov; 24(6):1-4. PubMed ID: 31801012
    [Abstract] [Full Text] [Related]

  • 17. Developmental toxicity assessment of tanezumab, an anti-nerve growth factor monoclonal antibody, in cynomolgus monkeys (Macaca fascicularis).
    Bowman CJ, Evans M, Cummings T, Oneda S, Butt M, Hurst S, Gremminger JL, Shelton D, Kamperschroer C, Zorbas M.
    Reprod Toxicol; 2015 Jun; 53():105-18. PubMed ID: 25461901
    [Abstract] [Full Text] [Related]

  • 18. Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients.
    Drerup KA, Seemann C, Gerdes S, Mrowietz U.
    Dermatology; 2022 Jun; 238(4):615-619. PubMed ID: 34775387
    [Abstract] [Full Text] [Related]

  • 19. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.
    Blauvelt A, Reich K, Papp KA, Kimball AB, Gooderham M, Tyring SK, Sinclair R, Thaçi D, Li Q, Cichanowitz N, Green S, La Rosa C.
    Br J Dermatol; 2018 Sep; 179(3):615-622. PubMed ID: 29742274
    [Abstract] [Full Text] [Related]

  • 20. Effect of ofatumumab on pregnancy, parturition, and lactation in cynomolgus monkeys.
    Bellot M, Luetjens CM, Bagger M, Horvath C, Sutter E, DeLise A, Brees D, Carballido JM, Pingili R, Ramanathan K, Kieseier BC, Hellwig K.
    Reprod Toxicol; 2022 Mar; 108():28-34. PubMed ID: 34942355
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.